Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares gapped up prior to trading on Wednesday. The stock had previously closed at $8.87, but opened at $9.65. Capricor Therapeutics shares last traded at $9.8020, with a volume of 832,911 shares trading hands.

Key Headlines Impacting Capricor Therapeutics

These are some of the CAPR headlines that stood out recently:

• Positive Sentiment: Capricor said Deramiocel’s application is in the FDA’s final review and reiterated confidence ahead of the Nov. 22 PDUFA date. The approaching decision is a major potential catalyst, though approval is not yet assured. CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision
• Neutral Sentiment: Capricor outlined manufacturing validation work extending into 2027. That provides a view of the company’s manufacturing plans, but the timeline may also leave questions about readiness to scale if Deramiocel is approved. Capricor Outlines 2027 Manufacturing Validation
• Negative Sentiment: Third-quarter results showed a loss of $0.73 per share, wider than analysts’ $0.44 loss estimate. The company also announced a 10% workforce reduction, underscoring efforts to manage costs amid ongoing development spending. Capricor Reports Third Quarter 2026 Results

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CAPR shares. Alliance Global Partners downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a report on Tuesday, July 28th. Maxim Group lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. JonesTrading downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st. B. Riley Financial raised shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $5.00 to $21.00 in a research note on Monday, September 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Friday, September 11th. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Hold” and an average target price of $30.25.

Capricor Therapeutics Stock Up 13.6%

The company has a market capitalization of $585.63 million, a PE ratio of -4.01 and a beta of 0.80. The firm’s 50-day moving average is $8.06 and its 200-day moving average is $20.05.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.29). As a group, equities research analysts predict that Capricor Therapeutics, Inc. will post -1.71 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CAPR. Activest Wealth Management boosted its holdings in shares of Capricor Therapeutics by 100.0% during the 3rd quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 2,000 shares in the last quarter. KBC Group NV purchased a new position in shares of Capricor Therapeutics during the first quarter valued at approximately $44,000. Russell Investments Group Ltd. lifted its holdings in shares of Capricor Therapeutics by 21.2% during the third quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 3,036 shares during the last quarter. VestGen Advisors LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter worth approximately $191,000. Finally, SBI Securities Co. Ltd. boosted its position in shares of Capricor Therapeutics by 834.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 23,495 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.